Daisuke Iwashima

Dr. Daisuke Iwashima

Kishiwada City Hospital, Ōsaka, Japan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KUKiyoshi Uemasu
Kiyoshi Uemasu
YYYuto Yasuda
Yuto Yasuda
YHYutaka Hirayama
Yutaka Hirayama
SASoichi Arasawa
Soichi Arasawa
DIDaisuke Iwashima
Daisuke Iwashima
KTKen-Ichi Takahashi
Ken-Ichi Takahashi

18 June 2022 in Respiratory Investigation
Verified
Journal Article
Closed access
YKYusuke Kawanaka
Yusuke Kawanaka
YYYuto Yasuda
Yuto Yasuda
JTJunko Tanizaki
Junko Tanizaki
DIDaisuke Iwashima
Daisuke Iwashima
YNYoshikane Nonagase
Yoshikane Nonagase
KTKen-Ichi Takahashi
Ken-Ichi Takahashi

9 December 2022 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
KFKana Fujimoto
Kana Fujimoto
SMSatoru Mutsuo
Satoru Mutsuo
YYYuto Yasuda
Yuto Yasuda
SASoichi Arasawa
Soichi Arasawa
NTNoriyuki Tashima
Noriyuki Tashima
KTKen-Ichi Takahashi
Ken-Ichi Takahashi
Background: The neutralizing ability of sotrovimab and casirivimab/imdevimab against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is attenuated in the subvariant BA.5. However, the efficacy of sotrovimab in the clinical setting remains to be investigated. Methods: Patients admitted to Kishiwada City Hospital with COVID-19 delta, omicron BA.1, or BA.5 subvariants were evaluated retrospectively for serum SARS-CoV-2 S and N antibody levels using the Elecsys Anti-SARS-CoV-2 assay. Results: In patients with COVID-19 during the BA.5 wave of the COVID-19 pandemic, anti-SARS-CoV-2 S antibody titers (median [interquartile range]) increased from 2154.0 (864.0–6669.3) U/mL on day 0 to 21,371.0 (19,656.3–32,225.0) U/mL on day 3 in the group treated with sotrovimab (N = 40) and were significantly higher than in the group treated with remdesivir plus dexamethasone plus baricitinib (p < 0.001). Conclusion: Treatment with sotrovimab could prevent severe disease in high-risk patients infected with SARS-CoV-2 subvariant BA.5.

6 April 2022 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
YYYuto Yasuda
Yuto Yasuda
SMSatoru Mutsuo
Satoru Mutsuo
MHMotoaki Hamada
Motoaki Hamada
KMKazuo Murai
Kazuo Murai
YHYutaka Hirayama
Yutaka Hirayama
KTKen-Ichi Takahashi
Ken-Ichi Takahashi
Background: Aluminium reduces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) survival in experimental settings. It is unknown whether adding an aluminium gauze to a mask reduces the SARS-CoV-2 RNA load in the mask and whether SARS-CoV-2 is detectable in the breath that permeates through such a mask in clinical settings. Methods: Patients admitted to Kishiwada City Hospital, Osaka, Japan, between July 2021 and September 2021 were enrolled in the study. Non-woven masks comprising filters with 99% viral filtration efficacy and aluminium and cotton gauzes attached to plastic collection cases were developed. All participants wore the experimental mask models for three hours. Results: Twenty-nine patients who wore the final model masks were analysed in this study. The Ct values of the nucleocapsid gene and envelope gene of SARS-CoV-2 were significantly higher in the aluminium gauze than in the cotton gauze. SARS-CoV-2 RNA was detected in the masks of 8 out of 12 vaccinated patients (66.7%). Although breath condensates were collected behind both aluminium and cotton gauzes, SARS-CoV-2 RNA was not detected in these condensates. Conclusions: Our study indicated that non-woven masks with an aluminium gauze may obstruct SARS-CoV-2 transmission in clinical settings better than non-woven masks with cotton gauzes.